Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Methyl nonanoate is a saturated fatty acid ester that has demonstrated diverse biological activities and applications. It has been identified as a volatile inhibitor of the Phosphatidylinositol-3-Kinase (PI3K) pathway, showing potential as an anticancer agent, particularly against lung cancer cells, with suggested administration via inhalers or sprays. Additionally, it exhibits antibacterial properties, inhibiting cariogenic bacteria such as *Streptococcus mutans* and *Lactobacillus acidophilus*. Methyl nonanoate also functions as an effective penetration enhancer, improving the transdermal delivery of various drugs including minoxidil, vitamin D3, erythromycin, triamcinolone acetonide, testosterone, and hydrocortisone.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Methyl nonanoate.